Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

43.54
-0.4600-1.05%
Post-market: 43.610.0700+0.16%19:56 EDT
Volume:2.31M
Turnover:100.67M
Market Cap:7.24B
PE:-12.51
High:44.17
Open:44.17
Low:43.24
Close:44.00
52wk High:86.74
52wk Low:43.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.63
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.45
PE(LYR):-18.28

Loading ...

Movement Alert|Ionis Pharmaceuticals Rises 5.15% in Regular Trading, Back-to-Back Phase 3 Wins Restore Market Confidence

Market Focus
·
Sep 29

Ionis Advances CHAMPION Phase 3 Trial in Angelman Syndrome, Raising Long‑Term Optionality for IONS Investors

TIPRANKS
·
Sep 29

Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 24

Ionis Pharmaceuticals Price Target Maintained with a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 24

Belgium's Celyad H1 Net Loss Narrows on Lower Expenses

Reuters
·
Sep 24

France's Abionyx Pharma H1 Net Loss Widens as Financial Expenses Rise

Reuters
·
Sep 24

Movement Alert|Ionis Pharmaceuticals Falls 5.05% in Regular Trading, Multiple Pipeline Wins Fail to Offset Lingering Cardiovascular Setback Sentiment

Market Focus
·
Sep 23

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 23

Movement Alert|Ionis Pharmaceuticals Rises 5.9% in Pre-Market Trading, Multiple Pipeline Catalysts as ALS and Kidney Disease Drugs Meet Phase 3 Endpoints

Market Focus
·
Sep 23

Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study

MT Newswires Live
·
Sep 23

Movement Alert|Ionis Pharmaceuticals Rises 5.9% Overnight, ALS Drug Ulefnersen Meets Primary Endpoint in Phase 3 Trial

Market Focus
·
Sep 23

Ionis Says Roche Phase 3 IMAgINATION Interim Data Show Sefaxersen Cuts Proteinuria in IgA Nephropathy

Reuters
·
Sep 23

Ionis Pharmaceuticals, - Sefaxersen Shows Statistically Significant Reduction in Proteinuria Versus Placebo at 37 Weeks

THOMSON REUTERS
·
Sep 23

Ionis Pharmaceuticals, - Imagination Study Meets Primary Endpoint with Sefaxersen at 37 Weeks

THOMSON REUTERS
·
Sep 23

Ionis Pharmaceuticals, - Sefaxersen Safety Profile Consistent with Previous Data, no New Safety Signals Identified

THOMSON REUTERS
·
Sep 23

Ionis Announces Positive Interim Data from Partner Roche’s Phase 3 Imagination Study in Iga Nephropathy (Igan)

THOMSON REUTERS
·
Sep 23

Ionis Pharmaceuticals, Inc.: Imagination Study Will Continue as a Blinded Study to Evaluate Change in Kidney Function over Two Years

THOMSON REUTERS
·
Sep 23

Otsuka, Ionis' Experimental ALS Drug Meets Main Goal in Late-Stage Study

Reuters
·
Sep 22

Movement Alert|Ionis Pharmaceuticals Rises 7.15% in Pre-Market Trading, Ulefnersen Phase 3 Trial in FUS-ALS Achieves Statistically Significant Improvement on Primary Endpoint

Market Focus
·
Sep 22

Ionis Says Phase 3 Fusion Trial Shows Ulefnersen Improves Function and Survival in FUS-ALS

Reuters
·
Sep 22